Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Prospective, multi-center, non-randomized, open label, clinical study intended to provide data to demonstrate safety and performance of the SoundBite Crossing System XS Peripheral.
The CaTO-PAD study includes a below-the-knee (BTK) sub-study (CaTO-BTK)
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| SoundBite Crossing System - PAD | Experimental | Use of the SoundBite Crossing System to cross calcified chronic total occlusions (above-the-knee or below-the-knee) |
|
| SoundBite Crossing System - BTK | Experimental | Use of the SoundBite Crossing System to cross calcified chronic total occlusions (below-the-knee) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| SoundBite Crossing System | Device | Use of the SoundBite Crossing System to cross calcified chronic total occlusions |
|
| Measure | Description | Time Frame |
|---|---|---|
| Device Performance | Crossing of the lesion regardless of method or modality (e.g., antegrade or retrograde) | Day 0 |
| Device Safety | Procedural incidence of any of the following: no reflow, thrombus formation, abrupt closure, distal embolization, dissection or perforation requiring treatment | Day 0 |
| Measure | Description | Time Frame |
|---|---|---|
| Antegrade Crossing | Placement of a guidewire distal to the lesion in the true lumen (Note: retrograde crossing is allowed, but is considered a failure for this endpoint) | Day 0 |
| CTO Crossing Time |
Not provided
Inclusion Criteria:
Scheduled for interventional treatment of de-novo lesion(s) of the following native arteries:
Have at least one chronic total occlusion (CTO) with no flow observed in the distal lesion except the flow from collateral circulation
Presenting with the following:
Age of > 18 years
Have been informed of the nature of the study, agrees to participate, and has signed the approved study consent form
Target lesion calcification is at least moderate by PARC definition (see Section 15)
Target lesion is refractory as demonstrated by a failed attempt with a guidewire
Exclusion Criteria:
Any medical condition that would make subject an inappropriate candidate for interventional treatment as determined by the Investigator, including the following:
Already enrolled in an investigational interventional study that would interfere with study endpoints
Target lesion is crossed intraluminally with a conventional guidewire
Treatment of an inflow lesion prior to target lesion treatment results in no reflow, thrombus formation, abrupt closure, distal embolization, dissection or perforation requiring treatment
Women who are pregnant or breastfeeding
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| John Schultz | Contact | 514-312-9181 | john.schultz@soundbitemedical.com |
| Name | Affiliation | Role |
|---|---|---|
| George Adams, MD | UNC REX Hospital, Raleigh, NC, USA | Principal Investigator |
| Michael Lichtenberg, MD | Angiology Clinic and Vascular Centre, Arnsberg, Germany | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Palm Vascular Centers | Recruiting | Fort Lauderdale | Florida | 33312 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
From first engagement of proximal cap with the Active Wire to guidewire in distal true lumen (or decision made to discontinue attempts)
| Day 0 |
| Acute Lumen Gain | Difference in final minimal lumen diameter compared to baseline | Day 0 |
| Residual Percent Stenosis | Final percent stenosis at procedure end | Day 0 |
| Procedure Time | First groin puncture to final sheath removal | Day 0 |
| Fluoroscopy Time | Day 0 |
| Number of Devices Used | Conventional guidewires, microcatheters, atherectomy devices, re-entry devices, balloons, stents | Day 0 |
| Secondary Safety Endpoint | Rate of 30-day major adverse events (MAE) consisting of: death, emergency surgical revascularization of the target limb, unplanned amputation of the target limb, symptomatic distal thrombus or emboli requiring intervention, perforation requiring treatment | Day 30 (+10/-0 days) |
| UNC REX Hospial | Not yet recruiting | Raleigh | North Carolina | 27607 | United States |
|
| Lifespan - The Miriam Hospital | Recruiting | Providence | Rhode Island | 02906 | United States |
|
| Medizinische Universität Graz | Not yet recruiting | Graz | Austria |
|
| Angiology Clinic and Vascular Centre | Not yet recruiting | Arnsberg | Germany |
|